SARS-CoV-2 infection in patients with inflammatory bowel disease : comparison between the first and second pandemic waves
© 2023. The Author(s)..
BACKGROUND: In Italy, the incidence of SARS-CoV-2 infection peaked in April and November 2020, defining two pandemic waves of coronavirus disease 2019 (COVID-19). This study compared the characteristics and outcomes of patients with inflammatory bowel disease (IBD) and SARS-CoV-2 infections between pandemic waves.
METHODS: Observational longitudinal study of IBD patients with SARS-CoV-2 infection. Patients with established diagnoses of IBD and of SARS-CoV-2 infection were consecutively enrolled in two periods: (i) first wave, from 1 March 2020 to 31 May 2020; and (ii) second wave, from 15 September to 15 December 2020.
RESULTS: We enrolled 937 IBD patients (219 in the first wave, 718 in the second wave). Patients of the first wave were older (mean ± SD: 46.3 ± 16.2 vs. 44.1 ± 15.4 years, p = 0.06), more likely to have ulcerative colitis (58.0% vs. 44.4%, p < 0.001) and comorbidities (48.9% vs. 38.9%; p < 0.01), and more frequently residing in Northern Italy (73.1% vs. 46.0%, p < 0.001) than patients of the second wave. There were no significant differences between pandemic waves in sex (male: 54.3% vs. 53.3%, p = 0.82) or frequency of active IBD (44.3% vs. 39.0%, p = 0.18). The rates of negative outcomes were significantly higher in the first than second wave: pneumonia (27.8% vs. 11.7%, p < 0.001), hospital admission (27.4% vs. 9.7%, p < 0.001), ventilatory support (11.9% vs. 5.4%, p < 0.003) and death (5.5% vs. 1.8%, p < 0.007).
CONCLUSION: Between the first and second SARS-CoV-2 pandemic waves, demographic, clinical and geographical features of IBD patients were different as were the symptoms and outcomes of infection. These differences are likely due to the different epidemiological situations and diagnostic possibilities between the two waves.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
BMC gastroenterology - 23(2023), 1 vom: 05. Juli, Seite 230 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bezzio, Cristina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 07.07.2023 Date Revised 18.07.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12876-023-02841-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359090591 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359090591 | ||
| 003 | DE-627 | ||
| 005 | 20231226080131.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12876-023-02841-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM359090591 | ||
| 035 | |a (NLM)37407913 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bezzio, Cristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 infection in patients with inflammatory bowel disease |b comparison between the first and second pandemic waves |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.07.2023 | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: In Italy, the incidence of SARS-CoV-2 infection peaked in April and November 2020, defining two pandemic waves of coronavirus disease 2019 (COVID-19). This study compared the characteristics and outcomes of patients with inflammatory bowel disease (IBD) and SARS-CoV-2 infections between pandemic waves | ||
| 520 | |a METHODS: Observational longitudinal study of IBD patients with SARS-CoV-2 infection. Patients with established diagnoses of IBD and of SARS-CoV-2 infection were consecutively enrolled in two periods: (i) first wave, from 1 March 2020 to 31 May 2020; and (ii) second wave, from 15 September to 15 December 2020 | ||
| 520 | |a RESULTS: We enrolled 937 IBD patients (219 in the first wave, 718 in the second wave). Patients of the first wave were older (mean ± SD: 46.3 ± 16.2 vs. 44.1 ± 15.4 years, p = 0.06), more likely to have ulcerative colitis (58.0% vs. 44.4%, p < 0.001) and comorbidities (48.9% vs. 38.9%; p < 0.01), and more frequently residing in Northern Italy (73.1% vs. 46.0%, p < 0.001) than patients of the second wave. There were no significant differences between pandemic waves in sex (male: 54.3% vs. 53.3%, p = 0.82) or frequency of active IBD (44.3% vs. 39.0%, p = 0.18). The rates of negative outcomes were significantly higher in the first than second wave: pneumonia (27.8% vs. 11.7%, p < 0.001), hospital admission (27.4% vs. 9.7%, p < 0.001), ventilatory support (11.9% vs. 5.4%, p < 0.003) and death (5.5% vs. 1.8%, p < 0.007) | ||
| 520 | |a CONCLUSION: Between the first and second SARS-CoV-2 pandemic waves, demographic, clinical and geographical features of IBD patients were different as were the symptoms and outcomes of infection. These differences are likely due to the different epidemiological situations and diagnostic possibilities between the two waves | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a Outcome | |
| 650 | 4 | |a Pandemic | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Vernero, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Armuzzi, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Fiorino, Gionata |e verfasserin |4 aut | |
| 700 | 1 | |a Ardizzone, Sandro |e verfasserin |4 aut | |
| 700 | 1 | |a Roselli, Jenny |e verfasserin |4 aut | |
| 700 | 1 | |a Carparelli, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Orlando, Ambrogio |e verfasserin |4 aut | |
| 700 | 1 | |a Caprioli, Flavio Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Castiglione, Fabiana |e verfasserin |4 aut | |
| 700 | 1 | |a Viganò, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Ribaldone, Davide G |e verfasserin |4 aut | |
| 700 | 1 | |a Zingone, Fabiana |e verfasserin |4 aut | |
| 700 | 1 | |a Monterubbianesi, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Imperatore, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Festa, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Daperno, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Scucchi, Ludovica |e verfasserin |4 aut | |
| 700 | 1 | |a Ferronato, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Pastorelli, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Alimenti, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Balestrieri, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Ricci, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Cappello, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Felice, Carla |e verfasserin |4 aut | |
| 700 | 1 | |a Coppini, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Alvisi, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Di Luna, Imma |e verfasserin |4 aut | |
| 700 | 1 | |a Gerardi, Viviana |e verfasserin |4 aut | |
| 700 | 1 | |a Variola, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzuoli, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Lenti, Marco Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Saibeni, Simone |e verfasserin |4 aut | |
| 700 | 0 | |a Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)’s COVID-19 Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Pugliese, Daniela |e investigator |4 oth | |
| 700 | 1 | |a Furfaro, Federica |e investigator |4 oth | |
| 700 | 1 | |a Maconi, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Milla, Monica |e investigator |4 oth | |
| 700 | 1 | |a Bossa, Fabrizio |e investigator |4 oth | |
| 700 | 1 | |a Giuliano, Alessandra |e investigator |4 oth | |
| 700 | 1 | |a Piazza, Nicole |e investigator |4 oth | |
| 700 | 1 | |a Manes, Gianpiero |e investigator |4 oth | |
| 700 | 1 | |a Sartini, Alessandro |e investigator |4 oth | |
| 700 | 1 | |a Buda, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Micheli, Federica |e investigator |4 oth | |
| 700 | 1 | |a Ciardo, Valeria |e investigator |4 oth | |
| 700 | 1 | |a Casella, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Viscido, Angelo |e investigator |4 oth | |
| 700 | 1 | |a Bodini, Giorgia |e investigator |4 oth | |
| 700 | 1 | |a Casini, Valentina |e investigator |4 oth | |
| 700 | 1 | |a Soriano, Alessandra |e investigator |4 oth | |
| 700 | 1 | |a Amato, Arnaldo |e investigator |4 oth | |
| 700 | 1 | |a Grossi, Laurino |e investigator |4 oth | |
| 700 | 1 | |a Onali, Sara |e investigator |4 oth | |
| 700 | 1 | |a Rottoli, Matteo |e investigator |4 oth | |
| 700 | 1 | |a Spagnuolo, Rocco |e investigator |4 oth | |
| 700 | 1 | |a Baroni, Stefania |e investigator |4 oth | |
| 700 | 1 | |a Cortelezzi, Claudio |e investigator |4 oth | |
| 700 | 1 | |a Baldoni, Monia |e investigator |4 oth | |
| 700 | 1 | |a Vernero, Marta |e investigator |4 oth | |
| 700 | 1 | |a Scaldaferri, Franco |e investigator |4 oth | |
| 700 | 1 | |a Maconi, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Guarino, Alessia |e investigator |4 oth | |
| 700 | 1 | |a Palermo, Andrea |e investigator |4 oth | |
| 700 | 1 | |a D'Incà, Renata |e investigator |4 oth | |
| 700 | 1 | |a Scribano, Maria Lia |e investigator |4 oth | |
| 700 | 1 | |a Biancone, Livia |e investigator |4 oth | |
| 700 | 1 | |a Carrozza, Lucio |e investigator |4 oth | |
| 700 | 1 | |a Ascolani, Marta |e investigator |4 oth | |
| 700 | 1 | |a Costa, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Di Sabatino, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Zammarchi, Irene |e investigator |4 oth | |
| 700 | 1 | |a Gottin, Matteo |e investigator |4 oth | |
| 700 | 1 | |a Conforti, Francesco Simone |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t BMC gastroenterology |d 2001 |g 23(2023), 1 vom: 05. Juli, Seite 230 |w (DE-627)NLM110904761 |x 1471-230X |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:05 |g month:07 |g pages:230 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12876-023-02841-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 05 |c 07 |h 230 | ||